BOT 1.54% 32.0¢ botanix pharmaceuticals ltd

2,036,444 Ordinary Shares -$0.053 per Ordinary Share735,829...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,400 Posts.
    lightbulb Created with Sketch. 560
    Column 1 Column 2 Column 3
    0 2,036,444 Ordinary Shares -$0.053 per Ordinary Share
    735,829 Ordinary Shares -$0.07 per Ordinary Share
    1 6
    Purpose of the issue
    (If issued as consideration for the acquisition of assets, clearly identify those assets)
    Exercise of Options

    Exercising of Options, from the resolution on the 14th of Nov 17.


    PS : from....

    https://www.********/investing/2018/05/06/3-reasons-regeneron-stock-could-start-climbing-aga.aspx

    .."As one of the first new eczema treatments for patients that aren't satisfied with topical steroids, Dupixent sales hit an annualized run rate of $556 million during its third quarter after earning approval in the U.S. That isn't nearly as fast as analysts had been predicted, but it still appears capable of generating more than $4 billion annually at its peak. .."
    Nice little earner
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
32.0¢
Change
-0.005(1.54%)
Mkt cap ! $581.5M
Open High Low Value Volume
32.5¢ 33.0¢ 32.0¢ $1.058M 3.280M

Buyers (Bids)

No. Vol. Price($)
2 147750 32.0¢
 

Sellers (Offers)

Price($) Vol. No.
32.5¢ 632850 6
View Market Depth
Last trade - 16.10pm 13/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.